Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Bicalutamide
Drug ID BADD_D00271
Description Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.
Indications and Usage For treatment (together with surgery or LHRH analogue) of advanced prostatic cancer.
Marketing Status Prescription; Discontinued
ATC Code L02BB03
DrugBank ID DB01128
KEGG ID D00961
MeSH ID C053541
PubChem ID 2375
TTD Drug ID D0V9BD
NDC Product Code 60429-177; 70518-2993; 51846-1028; 16714-816; 62559-680; 0904-6019; 16729-023; 43265-0705; 15308-0360; 54893-0001; 49711-1504; 65841-613; 43265-7195; 49711-1509; 71205-577; 68382-224; 47335-485; 63629-8308; 63759-0004; 62559-890; 53104-7664; 46014-1111; 58623-0068
Synonyms bicalutamide | 4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide | Casodex | Cosudex | ICI-176334 | ICI 176334
Chemical Information
Molecular Formula C18H14F4N2O4S
CAS Registry Number 90357-06-5
SMILES CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Disease progression08.01.03.0380.010928%
Hepatobiliary disease09.01.08.003--Not Available
Metastasis16.22.01.0010.006725%Not Available
Renal impairment20.01.03.0100.022556%Not Available
Unevaluable event08.01.03.051--Not Available
Osteonecrosis of jaw24.04.05.005; 15.02.04.0100.067667%
Bone marrow failure01.03.03.0050.012889%
Treatment failure08.06.01.0170.003362%Not Available
Liver injury12.01.02.003; 09.01.07.0220.006444%Not Available
Organising pneumonia22.01.02.0080.001681%Not Available
Type 2 diabetes mellitus05.06.01.003; 14.06.01.003--Not Available
Epidural lipomatosis17.10.01.012; 14.08.04.0190.006444%Not Available
Hypertransaminasaemia09.01.02.005--Not Available
Acute kidney injury20.01.03.0160.077334%
Drug-induced liver injury12.03.01.044; 09.01.07.0230.016111%Not Available
Hepatic cancer09.04.02.008; 16.07.02.0040.001681%Not Available
Hepatocellular carcinoma16.07.02.005; 09.04.02.0100.001681%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.010087%
Anal incontinence17.05.01.021; 07.01.06.0290.019333%
Liver function test increased13.03.01.0440.006444%Not Available
Blood testosterone abnormal13.10.05.0010.012889%Not Available
Chronic respiratory failure14.01.04.005; 22.02.06.0050.001681%Not Available
Cystitis radiation20.03.02.009; 12.05.02.0090.009667%Not Available
Metastases to bone16.22.02.005; 15.09.03.0060.048333%Not Available
Metastases to breast21.05.01.024; 16.22.02.0140.001681%Not Available
Metastases to lymph nodes16.22.02.006; 01.09.01.0150.004203%Not Available
Prostate cancer recurrent21.04.02.008; 16.25.01.0050.009667%Not Available
Prostatic haemorrhage24.07.03.028; 21.04.01.0090.009667%
Prostatic specific antigen decreased13.22.01.0020.006444%Not Available
Radiation proctitis12.05.02.012; 07.08.04.0030.006444%Not Available
The 16th Page    First    Pre   16 17    Next   Last    Total 17 Pages